Objective: Thromboembolus can occur during endovascular coil embolization. The aim of our study was to show our experience of intraarterial (IA) tirofiban infusion for thromboembolism during coil embolization for ruptured intracranial aneurysms. Methods: This retrospective analysis was conducted in 64 patients with ruptured aneurysms who had emergent endovascular coil embolization from May 2007 to April 2011 at a single institute. Thromboembolic events were found in ten patients (15.6%). Anticoagulation treatment with intravenous heparin was started after the first coil deployment in ruptured aneurysmal sac. When a thrombus or embolus was found during the procedure, we tried to resolve them without delay with an initial dosage of 0.3 mg of tirofiban up to 1.2 mg. Results: Three patients of four with total occlusion had recanalizations of thrombolysis in myocardial infarction (TIMI) grade III and five of six with partial occlusion had TIMI grade III recanalizations. Eight patients showed good recovery, with modified Rankin Scale (mRS) score of 0 and one showed poor outcome (mRS 3 and 6). There was no hemorrhagic or hematologic complication. Conclusion: IA tirofiban can be feasible when thromboembolic clots are found during coil embolization in order to get prompt recanalization, even in patients with subarachnoid hemorrhage.
INTRODUCTION
Thrombus can occur during endovascular coil embolization in ruptured aneurysms and it can lead to permanent ischemic injury to the brain if it is not combined with proper treatment. Several studies have been performed in order to find method to treat thromboembolus.
2)4)5)8)9) [12] [13] [14] [15] With no consensus on optimal thrombolytic drug yet, tirofiban or abciximab have been major treatment for resolving thrombus. The aim of study was to show our experience of intraarterial (IA) tirofiban for thromboembolism during emergent coil embolization in patients with ruptured intracranial aneurysms.
PATIENTS AND METHODS

Patients
This study was performed in patients who underwent endovascular coil embolization for ruptured aneurysm 
RESULTS
Ten patients received IA tirofiban and one received additional IV tirofiban for 24 hours after procedure for management of superior division of the M2 portion of a middle cerebral artery occlusion. The characteristics of the clots, the procedural types and medical devices are shown in Table 1 .
Complete arterial occlusion was found in four patients.
Three of them had TIMI grade III and one had TIMI grade I recanalization according to the subsequent angiogram. Five patients of six with partial occlusion had grade III and one had II recanalization (Table 2 ).
There was one who underwent by-pass operation due to failure of thrombolysis with IA tirofiban. Every patient underwent diffusion MRI in order to confirm the procedure of infarctions within 1 week. Diffusion restriction was found in six cases. Five patients of six showed small infarctions that were not correlated with their neurological examination, but one presented with significant infarction that lead to mRS score of 3.
Eight patients experienced good functional outcome (mRS score 0) and two showed poor outcome (3 and 6).
There were no hemorrhagic and hematologic complications in this study.
DISCUSSION
Thrombi can occur at interface between coil and parental artery or at remote lesions from the ruptured aneurysmal sac during the endovascular coil emboliza-tion for ruptured aneurysms. Several studies have revealed that thrombolytic agents, such as tirofiban and abciximab, can be effective to resolve thrombus or embolus during the procedure. There were no hemorrhagic complications in their study.
However, when urgent surgical operations are needed for ruptured aneurysms, there is the possibility of development of an ICH due to long infusion of tirofiban.
12)
Kang et al. 8) insisted that IA tirofiban was safe for thromboembolic complications during coil embolization.
They experienced 11 cases of ruptured aneurysms and 14 unruptured aneurysms. However, heparinization was started after the near occlusion of the ruptured sac in order to avoid ICH complications. In cases of thrombus formation, further packing of the coil to the aneurysmal sac was advanced rather than the immediate thrombolysis of the clot when its type was not complete occlusion.
Ries et al. 13) reported that IA or IV abciximab injections were safe in thromboembolic events with aneurysms. This drug did not increase the risk of hemorrhages in patients who were taking prophylactic aspirin or clopidogrel. They suggested that providing abciximab without delay after the detection of a thrombus was effective way to avoid hemorrhagic events.
In this study, anticoagulation with heparin was started just after the first coil was placed within the ruptured Considering its pharmacologic action and lasting duration, tirofiban is appropriate for these treatments.
Tirofiban has several pharmacological advantages over abciximab. It has a short half-life of 2 hours and platelet function is normalized 4 hours after discontinuation.
6)11)
Compared to IV infusion of tirofiban, IA injection can be performed directly to the thrombus through a highly selected artery and less of a dose can be used than that needed for the IV route, which is recommended. 8) There is concern about increasing the risk of hemorrhage when tirofiban was infused during the procedure in patients with aneurysmal SAH. 4)8) Although no hemorrhagic or hematologic complications found in this study, complications after using thrombolytic drugs were reported in previous studies.
1)3)7)12)
It is essential to get enough blood flow soon after the development of a thromboembolic event in order to prevent brain infarction. Thus, it is a good strategy to use tirofiban directly through a highly selective artery on a blood clot that was encountered during the operation without delay.
CONCLUSION
IA tirofiban infusion can be a feasible method when procedural thromboembolic complications occur, even in subarachnoid hemorrhage patients. Further investigation is needed to set clinical indications and dosage limitations of IA injection of tirofiban.
